ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1751

Disease activity, inflammation, and older age are associated with quantitative interstitial abnormalities in early RA: Results from a multicenter, prospective cohort study
Abstract Number: 1551

Disease Burden and Treatment Preferences for Systemic Lupus Erythematosus: Results from a Global Real-World Survey
Abstract Number: 0404

Disease Extension in Children with Limited Juvenile Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Abstract Number: 1844

Disease-Associated Macrophages Express an Injury-Associated Gene Program and Localize to Distinct Compartments in Proliferative and Mixed Histologic Classes of Lupus Nephritis
Abstract Number: 2199

Disparities in Reproductive Health Counseling Among Hispanic Women with Autoimmune Rheumatic Diseases: Insights from a Patient-Reported Survey in an Urban Safety-Net Setting
Abstract Number: 0104

Dissecting the Genetic and Functional Association of CARD9 with Axial Spondyloarthritis
Abstract Number: 1508

Dissecting the Role of T Cell Subsets and Complements in Lupus Pathogenesis in Systemic Lupus Erythematosus Patients with Obesity
Abstract Number: 0898

Distinct B Cell and Plasma Cell Immunosuppression Strategies Eliminate Antigen-Specific Cells of the B Lineage
Abstract Number: 0700

Distinct Breath Metabolomic Signature in Systemic Sclerosis Patients with Pulmonary Arterial Hypertension
Abstract Number: 0687

Distinct Cancer Risk Profiles in Patients with Systemic Sclerosis with Autoantibody Stratification
Abstract Number: 1101

Distinct Clinical Phenotypes of Immune Checkpoint Inhibitor–Associated Arthritis: Comparative Analysis of Inflammatory Arthritis, Polymyalgia Rheumatica-like, Activated Crystalline, and Activated Osteoarthritis
Abstract Number: 0759

Distinct differences between giant cell arteritis diagnosed by fluorodeoxyglucose (FDG) positron emission tomography (PET) versus temporal artery biopsy-a comparative cohort study
Abstract Number: 0988

Distinct Effects of Inhibitory Receptor Agonism on RA Synovial CD4+ T Cell Functions
Abstract Number: 2129

Distinct endotypes of SURF associated with clinical phenotypes, inflammatory cytokines, and treatment responses
Abstract Number: 0094

Distinct immune-molecular signatures modulated ex vivo by JAK and TNF predict Rheumatoid Arthritis therapy outcomes in patients naïve to biologic and targeted synthetic DMARDs

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].